uniQure N.V.
NASDAQ: QURE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Kapusta
- Employees
- 221
- Headquarters
- Amsterdam, Netherlands
- IPO year
- 2014
- Market cap
- $3.1B
- Website
- https://www.uniqure.com
Loading QURE…
Loading profile data…Frequently asked questions about QURE
What does uniQure N.V. (QURE) do?
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical...
Where does QURE trade?
uniQure N.V. (QURE) trades on the NASDAQ.
What sector is QURE in?
uniQure N.V. (QURE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of uniQure N.V.?
Matthew Kapusta is the chief executive officer of uniQure N.V. (QURE).
Where is uniQure N.V. headquartered?
uniQure N.V. is headquartered in Netherlands.
Does QURE pay a dividend?
uniQure N.V. (QURE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did QURE go public?
uniQure N.V. (QURE) completed its initial public offering in 2014.